Literature DB >> 8883398

p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma.

I B Runnebaum1, T Köhler, E Stickeler, H R Kieback, R Kreienberg.   

Abstract

Fallopian tube carcinoma (FTC) is a rare but lethal gynaecological malignancy. Four out of seven FTCs were identified with three point missense mutations, one single base deletion and one silent point mutation in the p53 gene. Genital-type HPV sequences were not detected. The S-phase fraction of tumours with mutant and wild-type p53 was 25.74% (median) and 12.55% (median) respectively.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8883398      PMCID： PMC2075926          DOI： 10.1038/bjc.1996.510

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  37 in total

1.  Overexpression and mutation of p53 in epithelial ovarian cancer.

Authors:  J R Marks; A M Davidoff; B J Kerns; P A Humphrey; J C Pence; R K Dodge; D L Clarke-Pearson; J D Iglehart; R C Bast; A Berchuck
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

2.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue].

Authors:  W Remmele; H E Stegner
Journal:  Pathologe       Date:  1987-05       Impact factor: 1.011

3.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

4.  Subcellular localization of accumulated p53 in ovarian cancer cells.

Authors:  I B Runnebaum; D G Kieback; V J Mobus; X W Tong; R Kreienberg
Journal:  Gynecol Oncol       Date:  1996-05       Impact factor: 5.482

5.  Fallopian tube cancer. The Roswell Park experience.

Authors:  P G Rose; M S Piver; Y Tsukada
Journal:  Cancer       Date:  1990-12-15       Impact factor: 6.860

6.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

Authors:  M Scheffner; B A Werness; J M Huibregtse; A J Levine; P M Howley
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

7.  Wild-type p53 can inhibit oncogene-mediated focus formation.

Authors:  D Eliyahu; D Michalovitz; S Eliyahu; O Pinhasi-Kimhi; M Oren
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

8.  Suppression of human colorectal carcinoma cell growth by wild-type p53.

Authors:  S J Baker; S Markowitz; E R Fearon; J K Willson; B Vogelstein
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

9.  Fallopian tube carcinoma.

Authors:  G L Eddy; L J Copeland; D M Gershenson; E N Atkinson; J T Wharton; F N Rutledge
Journal:  Obstet Gynecol       Date:  1984-10       Impact factor: 7.661

10.  Primary carcinoma of the fallopian tube--a retrospective analysis of 115 patients. Austrian Cooperative Study Group for Fallopian Tube Carcinoma.

Authors:  A Rosen; M Klein; M Lahousen; A H Graf; A Rainer; N Vavra
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640
View more
  1 in total

Review 1.  Primary fallopian tube cancer: a review of the literature.

Authors:  A C Hellström
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.